Abstract
The efficacy of PD-1 monoclonals such as pembrolizumab can be modulated by the signals delivered via their Fc region. Tumour/inflammation associated proteases can generate F(ab')(2) fragments of therapeutic monoclonals, and subsequent recognition of F(ab')(2) epitopes by circulating anti-hinge antibodies (AHA) can then, potentially, link F(ab')(2) binding to the target antigen with novel Fc signalling. Although elevated in inflammatory diseases, AHA levels in cancer patients have not been investigated and functional studies utilising the full repertoire of AHA present in sera have been limited. AHA levels in pembrolizumab treated melanoma patients (n = 23) were therefore compared to those of normal donors and adalimumab treated patients. A subset of melanoma patients and the majority of adalimumab patients had elevated levels of AHA reactive with F(ab')(2) fragments of IgG(4) anti-PD-1 monoclonals (nivolumab, pembrolizumab) and IgG(1) therapeutic monoclonals (rituximab, adalimumab). Survival analysis was restricted by the small patient numbers but those melanoma patients with the highest levels (>75% percentile, n = 5) of pembrolizumab-F(ab')(2) reactive AHA had significantly better overall survival post pembrolizumab treatment (p = 0.039). In vitro functional studies demonstrated that the presence of AHA(+) sera restored the neutrophil activating capacity of pembrolizumab to its F(ab')(2) fragment. Neither pembrolizumab nor its F(ab')(2) fragments can induce NK cell or complement dependent cytotoxicity (CDC). However, AHA(+) sera in combination with pembrolizumab-F(ab')(2) provided Fc regions that could activate NK cells. The ability of AHA(+) sera to restore CDC activity was more restricted and observed using only one pembrolizumab and one adalimumab patient serum in combination with rituximab- F(ab')(2). This study reports the presence of elevated AHA levels in pembrolizumab treated melanoma patients and highlight the potential for AHA to provide additional Fc signaling. The issue of whether tumour associated proteolysis of PD-1 mAbs and subsequent AHA recognition impacts on treatment efficacy requires further study.